A leader in conducting high-volume, complex and highly effective PCR testing. Mirimus has developed SalivaClear, a COVID-19 testing platform that combines saliva-based sampling, pooled testing and PCR diagnostics to improve the scalability, efficiency, cost-effectiveness and accuracy of COVID-19 testing. From the outset, Mitimus has been structured around creating genetically engineered mouse models with reverse gene silencing capabilities by harnessing the power of RNA interference, enabling clients to access better technologies for target identification, validation, toxicology assessment and disease modeling in vivo. Radically changing the way animal models by synergzing RNAi and CRISPR/Cas9 technologies for development of mice, rats and higher organisms, the firm is organized around design and development of new genome editing technologies to create and offer the animal models that are crucial for the preclinical evaluation of new therapeutics. With sophisticated and extensive expertise in the RNAi technologies that are critical for development of animal models that can pave the way drugs are deveoped: pin-pointing potential toxicities and guiding the process of creating safer, more effective therapeutics.
